%0 Journal Article %1 dreifaldt2019external %A Ann-Charlotte, Dreifaldt %A Bohr, Mordhorst Louise %A G, Sorbe Bengt %D 2019 %J Journal of Oncology Research and Therapy %K Boost Cervix External Prognosis beam cancer radiotherapy %N 01 %P 1-12 %T "External Beam Radiation Therapy Alone in the Treatment of Cervical Cancer: A Single-Institution Study on Efficacy and Safety" %U https://gavinpublishers.com/articles/Research-Article/Journal-of-Oncology-Research-and-Therapy-ISSN-2574-710X/external-beam-radiation-therapy-alone-in-the-treatment-of-cervical-cancer-a-single-institution-study-on-efficacy-and-safetyhttps://gavinpublishers.com/articles/Research-Article/Journal-of-Oncology-Research-and-Therapy-ISSN-2574-710X/external-beam-radiation-therapy-alone-in-the-treatment-of-cervical-cancer-a-single-institution-study-on-efficacy-and-safety %V 6 %X Purpose: The purpose of this study was to investigate the results regarding primary remission, recurrences, survival and toxicity when treating cervical cancer with external beam irradiation without addition of brachytherapy and to determine prognostic factors associated with these results. Material and Methods: The study included 111 consecutive patients treated with External Beam Radiotherapy (EBRT) alone at our department between 1993 and 2010. Patients treated with primary hysterectomy or brachytherapy were excluded. Twenty-seven patients had either strictly palliative treatment regimens or discontinued treatment and received 60 Gy or less. Eighty-four patients completed the planned treatment to 64.8-72.0 Gy with a combination of pelvic irradiation and an external boost to the tumor. Concurrent chemotherapy was given to 38 patients (34.2%). Results: The primary remission rate, 5-year Overall Survival (OS), and Cancer-Specific Survival (CSS) for the complete material was 62.2%, 19.5%, and 28.5%, respectively. For patients with non-metastatic cancer that received boost the primary remission rate, 5-year overall survival rate, and cancer-specific survival rate were 79.7%, 29.3% and 37.9%, respectively. The independent and significant prognostic factors for overall survival rate were: full treatment with boost, tumor histology, concurrent chemotherapy, and tumor stage. Severe early radiation reactions were reported in 12.6% of the patients and severe late reactions in 6.3%. Conclusions: The prognosis for patients receiving EBRT alone is markedly poorer than for those who receive a combination of EBRT and brachytherapy, although, a direct comparison cannot be made because of confounding factors. Brachytherapy should be used when technically possible. Concurrent chemotherapy should always be considered.

@article{dreifaldt2019external, abstract = {Purpose: The purpose of this study was to investigate the results regarding primary remission, recurrences, survival and toxicity when treating cervical cancer with external beam irradiation without addition of brachytherapy and to determine prognostic factors associated with these results. Material and Methods: The study included 111 consecutive patients treated with External Beam Radiotherapy (EBRT) alone at our department between 1993 and 2010. Patients treated with primary hysterectomy or brachytherapy were excluded. Twenty-seven patients had either strictly palliative treatment regimens or discontinued treatment and received 60 Gy or less. Eighty-four patients completed the planned treatment to 64.8-72.0 Gy with a combination of pelvic irradiation and an external boost to the tumor. Concurrent chemotherapy was given to 38 patients (34.2%). Results: The primary remission rate, 5-year Overall Survival (OS), and Cancer-Specific Survival (CSS) for the complete material was 62.2%, 19.5%, and 28.5%, respectively. For patients with non-metastatic cancer that received boost the primary remission rate, 5-year overall survival rate, and cancer-specific survival rate were 79.7%, 29.3% and 37.9%, respectively. The independent and significant prognostic factors for overall survival rate were: full treatment with boost, tumor histology, concurrent chemotherapy, and tumor stage. Severe early radiation reactions were reported in 12.6% of the patients and severe late reactions in 6.3%. Conclusions: The prognosis for patients receiving EBRT alone is markedly poorer than for those who receive a combination of EBRT and brachytherapy, although, a direct comparison cannot be made because of confounding factors. Brachytherapy should be used when technically possible. Concurrent chemotherapy should always be considered.}, added-at = {2019-05-02T12:17:47.000+0200}, author = {Ann-Charlotte, Dreifaldt and Bohr, Mordhorst Louise and G, Sorbe Bengt}, biburl = {https://www.bibsonomy.org/bibtex/293544217e64ac281410f90bf794dbee2/alyssacarter}, interhash = {9945589ae4b787eaedd846afd77272ad}, intrahash = {93544217e64ac281410f90bf794dbee2}, issn = {ISSN: 2574-710X}, journal = {Journal of Oncology Research and Therapy}, keywords = {Boost Cervix External Prognosis beam cancer radiotherapy}, language = {English}, month = {March}, number = 01, pages = {1-12}, timestamp = {2019-05-02T12:17:47.000+0200}, title = {"External Beam Radiation Therapy Alone in the Treatment of Cervical Cancer: A Single-Institution Study on Efficacy and Safety"}, url = {https://gavinpublishers.com/articles/Research-Article/Journal-of-Oncology-Research-and-Therapy-ISSN-2574-710X/external-beam-radiation-therapy-alone-in-the-treatment-of-cervical-cancer-a-single-institution-study-on-efficacy-and-safetyhttps://gavinpublishers.com/articles/Research-Article/Journal-of-Oncology-Research-and-Therapy-ISSN-2574-710X/external-beam-radiation-therapy-alone-in-the-treatment-of-cervical-cancer-a-single-institution-study-on-efficacy-and-safety}, volume = 6, year = 2019 }